Illumina(NASDAQ:ILMN) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Jul 26, 2016. Company reported revenue of $600.12M. Analysts estimated a revenue of $593.04M. Earnings per share were $0.86. Analysts had estimated an EPS of $0.73.
In a different note, On Jul 5, 2016, Morgan Stanley said it Downgrades its rating on Illumina. In the research note, the firm Lowers the price-target to $130.00 per share. The shares have been rated ‘Underweight’ by the firm. CL King said it Initiates Coverage on Illumina, according to a research note issued on Jun 22, 2016. The shares have been rated ‘Buy’ by the firm. On May 4, 2016, Citigroup said it Maintains its rating on Illumina. In the research note, the firm Lowers the price-target to $210.00 per share. The shares have been rated ‘Buy’ by the firm. On May 3, 2016, Morgan Stanley said it Maintains its rating on Illumina. In the research note, the firm Lowers the price-target to $140.00 per share. The shares have been rated ‘Equal-weight’ by the firm. On May 3, 2016, Nomura said it Maintains its rating on Illumina. In the research note, the firm Lowers the price-target to $210.00 per share. The shares have been rated ‘Buy’ by the firm.
Illumina (ILMN) shares turned negative on Fridays trading session with the shares closing down -0.07 points or -0.04% at a volume of 12,17,434. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $166.6299. The peak price level was also seen at $166.6299 while the days lowest was $163.11. Finally the shares closed at $166.35. The 52-week high of the shares is $220.86 while the 52-week low is $127.1. According to the latest information available, the market cap of the company is $24,487 M.
Several Insider Transactions has been reported to the SEC. On Jul 20, 2016, Robert S Epstein (director) sold 1,200 shares at $150.00 per share price.Also, On Jul 20, 2016, Jay T Flatley (director) sold 10,000 shares at $150.00 per share price.On Jul 15, 2016, A Blaine Bowman (director) sold 5,000 shares at $147.54 per share price, according to the Form-4 filing with the securities and exchange commission.
Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.